Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Prognostic Markers Identified in Ultra-Rare Adrenal Cancer

Oncotarget

January 26, 2022
Researchers demonstrated the overexpression of the protein APOBEC3B in adrenocortical carcinoma. They also identified the transcription factor, known as GATA3, that directly regulates APOBEC3B. continue reading »

Behind the Study: Prognostic Markers in Adrenocortical Carcinoma

Oncotarget

January 24, 2022
Dr. Monica Varun Tyagi discusses the research paper she co-authored that was published by Oncotarget, entitled, "GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3." continue reading »

Oncotarget’s Top 10 Most-Viewed Papers in 2021

Oncotarget

January 21, 2022
Read the 10 most-viewed oncology-focussed papers on Oncotarget.com in 2021. continue reading »

Gene Mutations and Neoantigens in Head and Neck Tumors

Oncotarget

January 13, 2022
The aim of this exploratory study was to characterize the genomic and neoantigen changes in 23 paired primary and recurrent head and neck cell squamous-cell carcinomas. continue reading »

Behind the Study: Genomic, Neoantigen Evolution in Head, Neck Cancer

Oncotarget

January 10, 2022
Drs. Brian Van Tine and Charles Schutt discuss their 2021 research paper, "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma." continue reading »